Table 1.
Selected characteristics at presentation in 21 heart failure patients and healthy donors
| Basic information | Heart failure patients n (percentage of 21) |
Healthy donors | p value |
|---|---|---|---|
| Age (years) | 34.6 ± 15.9 | 41.7 ± 4.0 | 0.07 |
| Male (percentage) | 13 (61.9) | 9(100) | 0.07 |
| NYHA functional class, n (percentage of 21) | |||
| II | 2 (9.5) | ||
| III | 7 (33.3) | ||
| IV | 12 (57.1) | ||
| Comorbidities | |||
| Diabetes mellitus | 2 (9.5) | ||
| Smoking history | 5 (23.8) | ||
| Pulmonary hypertension | 5 (23.8) | ||
| Tricuspid regurgitation | 12 (57.1) | ||
| Mitral regurgitation | 17 (81.0) | ||
| Ultrasonic cardiogram | |||
| LVEF (%) | 27.6 ± 9.8 | ||
| LA (mm) | 44.7 ± 4.8 | ||
| IVS-thickness (mm) | 8.2 ± 1.1 | ||
| LVEDD (mm) | 65.1 ± 16.6 | ||
| Arrhythmia history, n (percentage of 21) | |||
| Atrial fibrillation | 4 (19.0) | ||
| Premature ventricular contraction | 6 (28.6) | ||
| Ventricular tachycardia | 4 (19.0) | ||
| Ventricular fibrillation | 1 (4.8) | ||
| CRBBB | 3 (14.3) | ||
| Drug therapy, n (percentage of 21) | |||
| ASA | 2 (9.5) | ||
| Amio | 4 (19.0) | ||
| β-Blocker | 15 (71.4) | ||
| Digoxin | 16 (76.2) | ||
| ACEI/ARB | 17 (81.0) | ||
| CCB | 3 (14.3) | ||
| Diuretic | 18 (85.7) | ||